New York, Feb 6, 2026, 19:30 EST — After-hours
- JNJ climbed about 0.9% to $239.99 in after-hours trading.
- Beasley Allen, the plaintiffs’ firm, has been blocked by a New Jersey appeals court from representing claimants in specific state-level talc lawsuits targeting J&J.
- The FDA has issued a Class I recall for some CEREPAK detachable coil systems distributed by J&J’s MedTech division.
Johnson & Johnson shares ticked up on Friday, holding steady into after-hours. Investors weighed a New Jersey court’s latest move in the company’s ongoing talc litigation, along with a new FDA safety notice tied to select devices.
This legal battle still hangs over Johnson & Johnson, one of its largest sources of headline risk. Rulings can alter the tempo of ongoing litigation, shake up the power balance in settlement negotiations, and leave the final cost clouded in uncertainty for now.
Safety troubles with medical devices take their own shape, but the effect is familiar. When regulators slap a “Class I” tag on a recall—the FDA’s highest-risk designation—it can mean yanked products, supply headaches, and executives drawn into the aftermath.
Beasley Allen has been kicked off New Jersey’s consolidated talc cases by a three-judge panel from the state’s Superior Court Appellate Division, after judges found the firm improperly worked with a lawyer who once represented Johnson & Johnson in the same dispute. Judge Mark Chase flagged “clear concern for the preservation of trust intrinsic to the attorney-client relationship.” Beasley Allen plans to take the fight to the New Jersey Supreme Court. On the other side, Erik Haas, J&J’s worldwide litigation chief, slammed the firm’s actions as an “extraordinary and malicious” breach of ethics. Reuters
The stock advanced as U.S. equities rallied—S&P 500 jumped nearly 2%, Dow up around 2.5%—so Friday’s gain wasn’t easily traced back to any particular news. Reuters
The FDA disclosed that J&J MedTech and its Cerenovus unit are pulling certain CEREPAK detachable coil systems due to a higher-than-expected failure-to-detach rate, raising the risk of stroke, delays during procedures, or the need for extra intervention. According to the agency, the company had logged four serious injuries and one death tied to the defect as of Oct. 14, 2025. There’s no timeline for when the devices might return to market. U.S. Food and Drug Administration
Investors are left wondering if the legal decision actually moves the needle outside New Jersey state cases—and just how soon appeals take center stage. Another thing to watch: Will device headlines stick to that specific product list, or does scrutiny start creeping into related product lines?
There’s a clear risk here: Friday’s court victory might not hold. A higher court could overturn it, while a separate disqualification effort in federal court is still hanging in the balance. The bigger talc case load? Still just as unsettled and messy.
If things go south on the device front, it gets rough—more adverse-event reports, a longer period with the product off the market, or doctors shifting to rival brands as hospitals adapt. That would only add pressure to the MedTech unit, which is already contending with inconsistent procedure volumes in different categories.
Traders will be eyeing weekend headlines as they roll into Monday’s open, particularly any moves on appeal in New Jersey. Fresh updates are also set to emerge from J&J’s MedTech arm at the AFib Symposium in Boston, which continues through Feb. 7. The company reported it shared initial pilot findings from an investigational atrial fibrillation platform. “Pulse field ablation technologies should be individually evaluated for safety and reproducibility,” said Gregory Michaud, chief medical and scientific officer for electrophysiology. jnj.com
